Mitsubishi UFJ Asset Management
BPMC

Mitsubishi UFJ Asset Management’s Blueprint Medicines BPMC Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-58
Closed -$7.43K – 1610
2025
Q2 		$7.43K Hold
58
– – ﹤0.01% 1393
2025
Q1 		$5.13K Hold
58
– – ﹤0.01% 1433
2024
Q4 		$5.12K Hold
58
– – ﹤0.01% 1438
2024
Q3 		$5.37K Hold
58
– – ﹤0.01% 1399
2024
Q2 		$6.25K Hold
58
– – ﹤0.01% 1327
2024
Q1 		$5.5K Hold
58
– – ﹤0.01% 1314
2023
Q4 		$5.15K Hold
58
– – ﹤0.01% 1298
2023
Q3 		$2.91K Buy
+58
New +$3.1K ﹤0.01% 1513

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Mitsubishi UFJ Asset Management's BPMC Position: Q3 2025 in Review

Mitsubishi UFJ Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 58 shares — an estimated $7.43K sold.

Mitsubishi UFJ Asset Management first reported a position in BPMC in Q3 2023 and held it in 8 quarters. The position peaked at $7.43K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Mitsubishi UFJ Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management sold 58 Blueprint Medicines shares in Q3 2025, an estimated $7.43K.
  • Mitsubishi UFJ Asset Management first reported a position in Blueprint Medicines in Q3 2023 and held it in 8 quarters.
  • Mitsubishi UFJ Asset Management's Blueprint Medicines position peaked at $7.43K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.